Connect MM- The Multiple Myeloma Disease Registry
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 30 Aug 2017
At a glance
- Drugs Bortezomib (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 25 Aug 2017 Planned End Date changed from 1 Dec 2024 to 31 Dec 2024.
- 25 Aug 2017 Planned primary completion date changed from 1 Sep 2017 to 31 Dec 2024.
- 25 Jun 2017 Results assessing impact of post-autologous stem cell transplant maintenance therapy (lenalidomide (LEN)-based maintenance) on survival outcomes in patients with newly diagnosed multiple myeloma (cohort 1,n=432), presented at the 22nd Congress of the European Haematology Association.